Oncostatin M is overexpressed in NASH‐related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis
Open Access
- 7 March 2022
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 257 (1), 82-95
- https://doi.org/10.1002/path.5871
Abstract
Oncostatin M (OSM) is a pleiotropic cytokine of the interleukin (IL)-6 family that contributes to the progression of chronic liver disease. Here we investigated the role of OSM in the development and progression of hepatocellular carcinoma (HCC) in NAFLD/NASH. The role of OSM was investigated in: a) selected cohorts of NAFLD/NASH HCC patients; b) liver cancer cells exposed to human recombinant OSM or stably transfected to overexpress human OSM; c) murine HCC xenografts; d) a murine NASH-related model of hepatic carcinogenesis. OSM was found to be selectively overexpressed in HCC cells of NAFLD/NASH patients, depending on tumor grade. OSM serum levels, barely detectable in patients with simple steatosis or NASH, were increased in patients with cirrhosis, and more evident in those carrying HCC. In this latter group, OSM serum levels were significantly higher in the subjects with intermediate/advanced HCCs and correlated with poor survival. Cell culture experiments indicated that OSM upregulation in hepatic cancer cells contributes to HCC progression by inducing epithelial-to-mesenchymal transition and increased invasiveness of cancer cells as well as by inducing angiogenesis, which is of critical relevance. In murine xenografts, OSM overexpression was associated with slower tumor growth, but an increased rate of lung metastases. Overexpression of OSM and its positive correlation with the angiogenic switch were also confirmed in a murine model of NAFLD/NASH-related hepatocarcinogenesis. Consistent with this, analysis of liver specimens from human NASH-related HCCs with vascular invasion showed that OSM was expressed by liver cancer cells invading hepatic vessels. In conclusion, OSM up-regulation appears to be a specific feature of HCC arising on a NAFLD/NASH background, and it correlates with clinical parameters and disease outcome. Our data highlight a novel pro-carcinogenic contribution for OSM in NAFLD/NASH, suggesting a role of this factor as a prognostic marker and a putative potential target for therapy.Funding Information
- Associazione Italiana per la Ricerca sul Cancro (ID 12182, ID 17786, ID 18652, ID 20361, ID 22910)
- Università degli Studi di Padova (CPDA110795)
This publication has 62 references indexed in Scilit:
- Nonalcoholic Steatohepatitis and Noncirrhotic Hepatocellular Carcinoma: Fertile SoilSeminars in Liver Disease, 2012
- Oncostatin M Promotes Mammary Tumor Metastasis to Bone and Osteolytic Bone DegradationGenes & Cancer, 2012
- Exploring genomic profiles of hepatocellular carcinomaMolecular Carcinogenesis, 2011
- SERPINB3 induces epithelial–mesenchymal transitionThe Journal of Pathology, 2010
- Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular CarcinomaCancer Research, 2009
- Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cellsCytokine, 2006
- Oncostatin M-induced activation of stress-activated MAP kinases depends on tyrosine 861 in the OSM receptor and requires Jak1 but not Src kinasesCellular Signalling, 2006
- Expression of oncostatin M and its receptors in normal and cirrhotic human liverJournal of Hepatology, 2005
- Adaptor ShcA Protein Binds Tyrosine Kinase Tie2 Receptor and Regulates Migration and Sprouting but Not Survival of Endothelial CellsOnline Journal of Public Health Informatics, 2004
- Principles of interleukin (IL)-6-type cytokine signalling and its regulationBiochemical Journal, 2003